Vaccine Hesitancy refers to the reluctance or refusal to vaccinate despite the availability of vaccines, posing a significant challenge to public health efforts to control and prevent vaccine-preventable diseases. Vaccine hesitancy can stem from various factors, including concerns about vaccine safety, efficacy, and necessity, as well as misinformation, complacency, and lack of trust in healthcare systems or authorities. One of the primary drivers of vaccine hesitancy is misinformation and myths surrounding vaccines, fueled by social media, conspiracy theories, and anti-vaccine movements. These sources often spread false or misleading information about vaccine ingredients, side effects, and alleged risks, leading to confusion and distrust among the public.
Fear of adverse reactions or side effects is another common reason for vaccine hesitancy. While serious adverse events following vaccination are rare, they can occur, leading some individuals to perceive vaccines as unsafe or unnecessary. Addressing these concerns requires transparent communication about vaccine safety data, risk-benefit assessments, and the importance of vaccination in preventing serious diseases. Complacency, or the perception that vaccine-preventable diseases are no longer a threat, can also contribute to vaccine hesitancy. In communities where disease incidence is low or eradicated, individuals may underestimate the importance of vaccination and delay or forgo immunization, leading to outbreaks and resurgence of preventable diseases. Lack of trust in healthcare providers, pharmaceutical companies, or government authorities can further exacerbate vaccine hesitancy. Historical injustices, systemic inequalities, and incidents of medical malpractice or corruption may erode trust in vaccination programs and undermine confidence in vaccine recommendations.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States